Literature DB >> 18054636

Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients.

Sherri L Alexander1, Walter T Linde-Zwirble, Winifred Werther, Eric E Depperschmidt, Laura J Wilson, Ram Palanki, Namrata Saroj, Sara L Butterworth, Tsontcho Ianchulev.   

Abstract

PURPOSE: Smoking, age, and nutrition have been associated with the development of neovascular age-related macular degeneration (AMD) and can increase the risk of arterial thromboembolic events (ATEs). This study assesses annual rates of ATEs in new-onset neovascular AMD patients compared with matched controls.
DESIGN: Retrospective study. PARTICIPANTS: New-onset neovascular AMD patients and age-, race-, gender-, and database length-matched controls from the 5% Medicare database.
METHODS: We conducted a retrospective analysis of the 5% Medicare database from 2001 to 2003. New-onset neovascular AMD patients were included if they were > or =65 years old, had 2 diagnoses of neovascular AMD, and had at least 1 year of data before the first diagnosis of AMD within the dataset. A control group was constructed in a 3:1 ratio from those without a diagnosis of a major eye disorder and matched by age, race, gender, and length of data. Annual prevalence rates were determined for myocardial infarctions (MIs) and ischemic cerebral vascular accidents (CVAs). MAIN OUTCOME MEASURES: Rates of MIs and ischemic CVAs in new-onset neovascular AMD patients and matched controls from 2001 to 2003.
RESULTS: There were 15771 new-onset neovascular AMD patients identified and matched with 46 408 controls. Average age was 80.5 years, with 64% > or =80; 65% were female; and 95.9% were white. Inpatient MI rates for neovascular AMD patients and controls were 2.2% and 2.2%, respectively (P = 0.74). Inpatient ischemic CVA rates for neovascular AMD patients and controls were 3.5% and 3.6%, respectively (P = 0.59). Myocardial infarction rates and ischemic CVA rates for both groups increased with age. Subgroups of patients with comorbidities known to be risk factors for ATEs (i.e., hypertension, hyperlipidemia, diabetes, and arrhythmias) had a higher rate of events. Patients with previous ATEs were also at a higher risk of subsequent events, at 7.4% for inpatient MI and 35.1% for inpatient ischemic stroke.
CONCLUSION: Despite the shared risk factors associated with neovascular AMD and ATEs, Medicare beneficiaries with neovascular AMD had a rate of ATEs similar to that of matched controls. Rates of ATEs increased in patients with comorbidities and for patients with previous events.

Entities:  

Mesh:

Year:  2007        PMID: 18054636     DOI: 10.1016/j.ophtha.2007.09.017

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  15 in total

1.  [New aspects in the therapy of neovascular age related macular degeneration. Current position of the Retinological Society, the Germany Ophthalmologic Society and the Professional Union of Eye Doctors of Germany].

Authors: 
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

2.  Coronary Artery Disease and Reticular Macular Disease, a Subphenotype of Early Age-Related Macular Degeneration.

Authors:  Rachel M Cymerman; Adam H Skolnick; William J Cole; Camellia Nabati; Christine A Curcio; R Theodore Smith
Journal:  Curr Eye Res       Date:  2016-05-09       Impact factor: 2.424

3.  Ischaemic colitis associated with intravitreal administration of aflibercept: A first case report.

Authors:  Benjamin Batteux; Valérie Gras; Yanis Mahboud; Sophie Liabeuf; Youssef Bennis; Kamel Masmoudi
Journal:  Br J Clin Pharmacol       Date:  2019-02-01       Impact factor: 4.335

4.  Subretinal Drusenoid Deposits and Lower Serum High-Density Lipoprotein Cholesterol Levels Possess Latent Relation to Cardiovascular Disease and Can Be a Feasible Predictor.

Authors:  Changsen Liang; Ning Wang
Journal:  Comput Math Methods Med       Date:  2022-07-01       Impact factor: 2.809

5.  Introducing Anti-Vascular Endothelial Growth Factor Therapies for AMD Did Not Raise Risk of Myocardial Infarction, Stroke, and Death.

Authors:  Arseniy P Yashkin; Paul Hahn; Frank A Sloan
Journal:  Ophthalmology       Date:  2016-08-11       Impact factor: 12.079

6.  Longitudinal incidence of adverse outcomes of age-related macular degeneration.

Authors:  Ashley Wysong; Paul P Lee; Frank A Sloan
Journal:  Arch Ophthalmol       Date:  2009-03

7.  Role of statins in the development and progression of age-related macular degeneration.

Authors:  Brian L VanderBeek; David N Zacks; Nidhi Talwar; Bin Nan; Joshua D Stein
Journal:  Retina       Date:  2013-02       Impact factor: 4.256

Review 8.  Age-Related Macular Degeneration and Incident Stroke: A Systematic Review and Meta-Analysis.

Authors:  Antonio B Fernandez; Gregory A Panza; Benjamin Cramer; Saurav Chatterjee; Ramya Jayaraman; Wen-Chih Wu
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

9.  Comparison of systemic adverse events associated with intravitreal anti-VEGF injection: ranibizumab versus bevacizumab.

Authors:  Duck Jin Hwang; Yong Woo Kim; Se Joon Woo; Kyu Hyung Park
Journal:  J Korean Med Sci       Date:  2012-12-07       Impact factor: 2.153

Review 10.  What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?

Authors:  Robert L Avery
Journal:  Br J Ophthalmol       Date:  2013-12-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.